Compare Humana Inc (HUM) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Invesco Ltd. — how do they compare? Humana Inc trades at $374.25 (market cap $46.31B), while Invesco Ltd. trades at $31.16 (market cap $14.01B). The key difference: Humana Inc is far larger — about 3.3× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.71%). Which is the better fit depends on your goals.
| HUM | IVZ | |
|---|---|---|
Market Cap | $46.31B | $14.01B |
Sector | Health | Financials |
52-Week High | $409.42 | $32.01 |
52-Week Low | $163.67 | $20.45 |
Enterprise Value | $53.67B | $24.18B |
Dividend Yield | 0.92% | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
Invesco (IVZ) trades at $31.58, near its 52-week high, with a bullish technical signal from moving averages and recent record inflows driving AUM growth. The company reported mixed quarterly EPS results but shows improving cash flow trends, with 2025 operating cash flow at $1.53 billion. Analyst consensus is divided, with 42.9% buy ratings and a $32.50 price target, while negative net income margins and ROE highlight profitability challenges.
The outlook is cautiously optimistic due to strong institutional interest and dividend consistency, but risks include expense pressures and volatile earnings. Investors should weigh the bullish technicals and asset growth against fundamental weaknesses in profitability and margin compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
